Clinical Trial

Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study evaluate the efficacy of Tafasitamab and Lenalinomide associated to Rituximab in elderly patients with frontline Diffuse Large B-Cell Lymphoma as assessed by the Overall Response Rate (ORR) after 3 cycles of treatment according to Lugano Response Criteria.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2021-07-22; most recent amendment 2026-06-02.
Status change: Recruiting → Active, Not Recruiting 2024-10-08
Status change: Not Yet Recruiting → Recruiting 2022-03-03
Trial Details
NCT Number NCT04974216
Lead Sponsor The Lymphoma Academic Research Organisation
Conditions DLBCL
Enrollment 71 participants
Start Date 2021-12-20
Primary Completion 2024-07-15 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-04